HealthDay News — Among healthy, young adults, those who are seropositive rather than seronegative for SARS-CoV-2 have a reduced risk for subsequent SARS-CoV-2 infection, about one-fifth the risk for infection compared with seronegative participants, according to a study published online April 15 in The Lancet Respiratory Medicine.

Andrew G. Letizia, MD, from the Naval Medical Research Center in Silver Spring, Maryland, enrolled predominantly male US Marine recruits, aged 18 to 20 years, following a 2-week unsupervised quarantine at home. After the home quarantine period, participants were assessed for baseline SARS-CoV-2 immunoglobulin G (IgG) positivity and underwent a supervised two-week quarantine period. Participants with three negative results during quarantine and a baseline serum serology test were included in the study; both seropositive and seronegative groups underwent 3 SARS-CoV-2 tests at weeks 2, 4, and 6 in a prospective study.

The researchers enrolled 3249 participants, of whom 98% continued into the 2-week quarantine period. Ninety-five percent of participants were followed during the prospective study period. Of 189 seropositive participants, during the 6-week follow-up, 10% had at least one positive test for SARS-CoV-2 (1.1 cases per person-year). Among 2247 seronegative participants, 48% tested positive (6.2 cases per person-year). The incidence rate ratio was 0.18. Infection was more likely among seropositive recruits with lower versus higher baseline full-length spike protein IgG titers (hazard ratio, 0.45). Compared with infected seronegative participants, infected seropositive participants had viral loads that were about 10 times lower.

“Our results indicate that although antibodies induced by infection are largely protective, they do not guarantee effective immunity against subsequent infection,” the authors write.

Continue Reading

One author disclosed financial ties to Co-Diagnostics; two authors have filed a patent regarding serological assays for SARS-CoV-2.

Abstract/Full Text